Cholesterol

Cholesterol

SCHEMBL161748

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.CCCCCCCCCCCCCC(=O)O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 3/20 0.79
▸ RORC P51449 2/20 0.79
▸ USP2 O75604 1/20 0.79
▸ LMNA P02545 1/20 0.79
▸ ABCB1 P08183 1/20 0.79
▸ OSBP2 Q969R2 1/20 0.79
▸ CYP46A1 Q9Y6A2 1/20 0.79
▸ NR1H3 Q13133 6/20 0.77
▸ EPHA2 P29317 1/20 0.77
▸ GRIN1 Q05586 1/20 0.68
▸ GRIN2A Q12879 1/20 0.68
▸ NPC1L1 Q9UHC9 2/20 0.67
▸ POLA1 P09884 1/20 0.67
▸ DHCR24 Q15392 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL970382 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL9566174 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL7736671 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL2195602 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL10933840 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL25174230 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL16415838 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL10883099 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL22749559 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1
Cholesterol SCHEMBL892123 1.00 OSBP (0.79) OSBPRORCUSP2LMNAABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12233034-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2025-02-25 — — US claimed
CN-118086186-B Use of ethyl stearate in combination with cholesterol myristate 广州中医药大学(广州中医药研究院) 2024-08-02 — — CN claimed
CN-118141908-A Lymph targeting tumor nano vaccine and application thereof 中国药科大学 2024-06-07 — — CN claimed
CN-118086186-A Use of ethyl stearate in combination with cholesterol myristate 广州中医药大学(广州中医药研究院) 2024-05-28 — — CN claimed
CN-118086184-A Application of tortoise plastron extract combined with cholesterol myristate 广州中医药大学(广州中医药研究院) 2024-05-28 — — CN claimed
CN-115851087-B Blue light diffusion prevention coating and application thereof 广东粤港澳大湾区黄埔材料研究院 2023-10-10 — — CN claimed
CN-115851087-A Blue light diffusion preventing coating and application thereof 广东粤港澳大湾区黄埔材料研究院 2023-03-28 — — CN claimed
EP-4025660-A1 THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS Sun Chemical Corporation (US) 2022-07-13 — — EP claimed
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CLARIDEI LABORATORIES, INC. 2022-02-03 — — US claimed
CN-113679689-A Compositions and methods for nanoparticle lyophilisate form 日东电工株式会社 2021-11-23 — — CN claimed
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2018-10-11 — — US claimed
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2016-06-30 — — US claimed
EP-3024438-A1 FORMULATIONS FOR EPIDERMAL REPAIR Eberting, Cheryl Lee (US) 2016-06-01 — — EP claimed
EP-2853264-A1 Nanodispersion Sun Pharma Advanced Research Company Limited (IN) 2015-04-01 — — EP claimed
WO-2015013634-A1 FORMULATIONS FOR EPIDERMAL REPAIR EBERTING CHERYL LEE (US) 2015-01-29 — — WO claimed
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents L'OREAL S.A. (FR) 2006-06-01 — — US claimed
EP-1647259-A1 use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals L'OREAL (FR) 2006-04-19 — — EP claimed
US-6328910-B1 FOR IN SITU FORMATION OF AN POLYMERIC CYANOACRYLATE FILM ON MAMMALIAN SKIN WHICH CAN BE USED TO MONITOR THE SURFACE SKIN TEMPERATURE OF MAMMAL MEDLOGIC GLOBAL CORPORATION 2001-12-11 — — US claimed
US-5885565-A APPLYING TO THE EPITHELIUM OF THE HOST, AN EFFECTIVE AMOUNT OF ONE OR MORE PENETRATION ENHANCING EPITHELIAL STEROLS AND THERAPEUTICAL OR PROPHYLACTIC AGENT CELLEGY PHARMACEUTICALS INC. (US) 1999-03-23 — — US claimed
CN-86108433-A Polymer/liquid crystal composition semi-permeable membranes and using method thereof — 1987-07-29 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233034-B2 Formulations for epidermal repair KRT18, CUTA, DSG1 OSBP 857/4885RORC 356/4885USP2 1927/4885
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 OSBP 975/4885RORC 377/4885USP2 1921/4885
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 OSBP 857/4885RORC 356/4885USP2 1927/4885
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents KRT18, PRKDC, CUTA OSBP 2396/4885RORC 3212/4885USP2 2505/4885
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CUTA, EPHB1, EPHB2 OSBP 780/4885RORC 281/4885USP2 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback